The inflammatory response in sepsis

Trends in Immunology

Volumn 34, Issue 3, 2013, Pages 129-136

  Bosmann, Markus ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; HORMONE RECEPTOR; MITOCHONDRIAL ENZYME;

AUTONOMIC NERVOUS SYSTEM; COMPLEMENT ACTIVATION; DEATH; ENZYME ACTIVATION; HEMORRHAGIC SHOCK; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LETHALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PHAGOCYTE; PROTEIN FUNCTION; REVIEW; SEPSIS; SYMPATHETIC NERVE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; PHAGOCYTOSIS; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84875262757     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.09.004     Document Type: Review

References (66)

1. Martin G.S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2003, 348:1546-1554.
2. Coopersmith C.M., et al. A comparison of critical care research funding and the financial burden of critical illness in the United States. Crit. Care Med. 2012, 40:1072-1079.
3. Angus D.C. The search for effective therapy for sepsis: back to the drawing board?. JAMA 2011, 306:2614-2615.
4. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants?. J. Leukoc. Biol. 2010, 87:989-999.
5. Clark J.A., Coopersmith C.M. Intestinal crosstalk: a new paradigm for understanding the gut as the 'motor' of critical illness. Shock 2007, 28:384-393.
6. Cai B., et al. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010, 2010:642462.
7. Ward P.A. The harmful role of C5a on innate immunity in sepsis. J. Innate Immun. 2010, 2:439-445.
8. Andrades M., et al. Bench-to-bedside review: sepsis - from the redox point of view. Crit. Care 2011, 15:230.
9. Berger M.M., Chiolero R.L. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit. Care Med. 2007, 35:S584-S590.
10. Crimi E., et al. Role of oxidative stress in experimental sepsis and multisystem organ dysfunction. Free Radic. Res. 2006, 40:665-672.
11. von Dessauer B., et al. Oxidative stress as a novel target in pediatric sepsis management. J. Crit. Care 2011, 26:103.e101-103.e107.
12. van Berlo D., et al. Neutrophil-derived ROS contribute to oxidative DNA damage induction by quartz particles. Free Radic. Biol. Med. 2010, 49:1685-1693.
13. Moore S.F., MacKenzie A.B. NADPH oxidase NOX2 mediates rapid cellular oxidation following ATP stimulation of endotoxin-primed macrophages. J. Immunol. 2009, 183:3302-3308.
14. Lipinski B. Hydroxyl radical and its scavengers in health and disease. Oxid. Med. Cell. Longev. 2011, 2011:809696.
15. Valko M., et al. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
16. Martin L.J. DNA damage and repair: relevance to mechanisms of neurodegeneration. J. Neuropathol. Exp. Neurol. 2008, 67:377-387.
17. Zakkar M., et al. Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1851-1857.
18. MacGarvey N.C., et al. Activation of mitochondrial biogenesis by heme oxygenase-1-mediated NF-E2-related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis. Am. J. Respir. Crit. Care Med. 2012, 185:851-861.
19. Kong X., et al. Enhancing Nrf2 pathway by disruption of Keap1 in myeloid leukocytes protects against sepsis. Am. J. Respir. Crit. Care Med. 2011, 184:928-938.
20. Bell K.F., et al. Activation of Nrf2-regulated glutathione pathway genes by ischemic preconditioning. Oxid. Med. Cell. Longev. 2011, 2011:689524.
21. Kensler T.W., Wakabayashi N. Nrf2: friend or foe for chemoprevention?. Carcinogenesis 2010, 31:90-99.
22. Sirgo G., et al. Dendritic cells in sepsis: an approach to post-infectious immunosuppression. Med. Intensiva 2010, 34:559-566. (in Spanish).
23. Scumpia P.O., et al. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J. Immunol. 2005, 175:3282-3286.
24. Delano M.J., et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J. Immunol. 2011, 186:195-202.
25. Polvani S., et al. PPARgamma and oxidative stress: con(beta) catenating NRF2 and FOXO. PPAR Res. 2012, 2012:641087.
26. Kaplan J.M., Zingarelli B. Novel therapeutic agents in pediatric sepsis: peroxisome proliferator receptor gamma (PPAR gamma) agonists. Open Inflamm. J. 2011, 4:120-124.
27. Barrera G., et al. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products. PPAR Res. 2008, 2008:524671.
28. Choi J.H., et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477:477-481.
29. Standage S.W., et al. Reduced peroxisome proliferator-activated receptor alpha expression is associated with decreased survival and increased tissue bacterial load in sepsis. Shock 2012, 37:164-169.
30. Vachharajani V., et al. Curcumin modulates leukocyte and platelet adhesion in murine sepsis. Microcirculation 2010, 17:407-416.
31. Sun Y., Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res. 2007, 2007:23513.
32. Khazaei M., et al. Pan-PPAR agonist, bezafibrate, restores angiogenesis in hindlimb ischemia in normal and diabetic rats. Int. J. Pept. 2012, 10.1155/2012/637212.
33. Mathews M.T., Berk B.C. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler. Thromb. Vasc. Biol. 2008, 28:711-717.
34. Bamberg C.E., et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 2010, 285:7633-7644.
35. Bosmann M., et al. Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages. J. Immunol. 2012, 188:5086-5093.
36. Speyer C.L., Ward P.A. Role of endothelial chemokines and their receptors during inflammation. J. Invest. Surg. 2011, 24:18-27.
37. Andersson U., Tracey K.J. Reflex principles of immunological homeostasis. Annu. Rev. Immunol. 2012, 30:313-335.
38. Borovikova L.V., et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton. Neurosci. 2000, 85:141-147.
39. Bonaz B. The cholinergic anti-inflammatory pathway and the gastrointestinal tract. Gastroenterology 2007, 133:1370-1373.
40. Kamal A. Assessment of autonomic function in patients with rheumatoid arthritis using spectral analysis and approximate entropy method. Neurosciences (Riyadh) 2007, 12:136-139.
41. Stojanovich L., et al. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjogren syndrome and other autoimmune diseases. Lupus 2007, 16:181-185.
42. Pierrakos C., et al. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J. Clin. Med. Res. 2012, 4:7-16.
43. Matthay M.A., et al. The acute respiratory distress syndrome. J. Clin. Invest. 2012, 122:2731-2740.
44. Flierl M.A., et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007, 449:721-725.
45. Bosmann M., et al. Anti-inflammatory effects of beta2 adrenergic receptor agonists in experimental acute lung injury. FASEB J. 2012, 26:2137-2144.
46. Boomer J.S., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
47. Ward P.A. Immunosuppression in sepsis. JAMA 2011, 306:2618-2619.
48. Hotchkiss R.S., et al. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 2009, 15:496-497.
49. Takahashi H.K., et al. Activation of survival and apoptotic signaling pathways in lymphocytes exposed to palmitic acid. J. Cell. Physiol. 2012, 227:339-350.
50. Warner E.A., Moldawer L.L. Using innate immunity to characterize the host response to microbial invasion in severe sepsis. Future Microbiol. 2008, 3:177-189.
51. Unsinger J., et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 2010, 184:3768-3779.
52. Sereti I. Where have all the T cells gone?. Blood 2009, 114:751-752.
53. Inoue S., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 2010, 184:1401-1409.
54. Dejager L., et al. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?. Trends Microbiol. 2011, 19:198-208.
55. Rittirsch D., et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 2009, 4:31-36.
56. Lissauer M.E., et al. Differential expression of toll-like receptor genes: sepsis compared with sterile inflammation 1 day before sepsis diagnosis. Shock 2009, 31:238-244.
57. Remick D.G., Ward P.A. Evaluation of endotoxin models for the study of sepsis. Shock 2005, 24(Suppl. 1):7-11.
58. Schmidt W.M., et al. In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem. Biophys. Res. Commun. 2009, 380:437-441.
59. Zanotti-Cavazzoni S.L., Goldfarb R.D. Animal models of sepsis. Crit. Care Clin. 2009, 25:703-719.
60. Fink M.P. Animal models of sepsis and its complications. Kidney Int. 2008, 74:991-993.
61. Dyson A., Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?. Crit. Care Med. 2009, 37:S30-S37.
62. Doi K., et al. Animal models of sepsis and sepsis-induced kidney injury. J. Clin. Invest. 2009, 119:2868-2878.
63. Silva E., et al. Sepsis: from bench to bedside. Clinics (Sao Paulo) 2008, 63:109-120.
64. Cavassani K.A., et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 2010, 115:4403-4411.
65. Angus D.C. The lingering consequences of sepsis: a hidden public health disaster?. JAMA 2010, 304:1833-1834.
66. Lopes J.A., et al. Long-term risk of mortality after acute kidney injury in patients with sepsis: a contemporary analysis. BMC Nephrol. 2010, 11:9.